Drug · CHEMBL1503
OMEPRAZOLE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. OMEPRAZOLE. Drugs and targets, record CHEMBL1503. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1503
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
Antra, Losec, Losec mups, Mezzopram, Mopral, Omeprazole component of konvomep, Omeprazole component of pa-32540, Omeprazole component of yosprala, Omeprazole component of zegerid, Omeran, Prilosec, Zanprol
- ChEMBL
- Open Targets' highest stage
- Approval, for 12 of its 55 diseases, from ATC, DailyMed and TTD
- Open Targets
Targets2
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| ATP4A | Potassium-transporting ATPase | Potassium-transporting ATPase inhibitor | INHIBITOR | https://conductscience.org/library/genes/495 |
| ATP4B | Potassium-transporting ATPase | Potassium-transporting ATPase inhibitor | INHIBITOR | https://conductscience.org/library/genes/496 |
Source ChEMBL
Diseases55
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 55Source Open Targets
See all 55 diseasesTrials369
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 6 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 4 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00141102 | Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis | Phase 4 | 4,484 | 2010-06-11 | omeprazole | Its name | ClinicalTrials.gov |
| NCT00633932 | Reflux Esophagitis Phase III Study (Initial Treatment) | Phase 3 | 602 | 2010-04-08 | omeprazole | Its name | ClinicalTrials.gov |
| NCT00634114 | Reflux Esophagitis Phase III Study (Maintenance Treatment) | Phase 3 | 540 | 2010-06-17 | omeprazole | Its name | ClinicalTrials.gov |
| NCT00961350 | A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers | Phase 3 | 530 | 2016-01-21 | PA32540 | Open Targets' reading, confirmed by the trial's result groups | ClinicalTrials.gov |
| NCT00960869 | Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers | Phase 3 | 519 | 2016-02-17 | pa32540 | Open Targets' reading, confirmed by the trial's result groups | ClinicalTrials.gov |
| NCT01499368 | A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients | Phase 3 | 495 | 2020-09-16 | omeprazole | Its name | ClinicalTrials.gov |
| NCT03198507 | ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator | Phase 3 | 455 | 2020-03-16 | RHB-105 | Open Targets' reading, confirmed by the trial's result groups and NLM's indexing of its papers | ClinicalTrials.gov |
| NCT00669955 | Efficacy and Safety of Quadruple Therapy in Eradication of H. Pylori: A Comparison to Triple Therapy | Phase 3 | 440 | 2010-08-05 | omeprazole | Its name | ClinicalTrials.gov |
| NCT00995410 | Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers | Phase 3 | 380 | 2016-02-17 | pa32540 | Open Targets' reading, confirmed by the trial's result groups and NLM's indexing of its papers | ClinicalTrials.gov |
| NCT04039412 | Comparison Between Quadruple Regimens for Helicobacter Pylori Infection in Egypt | Phase 4 | 330 | 2019-11-26 | omeprazole | Its name | ClinicalTrials.gov |
1 to 10 of 369
See all 369 trialsComparisons in its trials75
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs) | 20 of 2,238 | 81 of 2,246 | 4,484 | NCT00141102 | Trial comparisons |
| Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects With Moderate to Severe Abdominal Symptoms | 132 of 2,238 | 162 of 2,246 | 4,484 | NCT00141102 | Trial comparisons |
| Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects With SUs | 5 of 2,238 | 11 of 2,246 | 4,484 | NCT00141102 | Trial comparisons |
| Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects With CSULGIES or Symptomatic Ulcers (SUs) | 25 of 2,238 | 92 of 2,246 | 4,484 | NCT00141102 | Trial comparisons |
| Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects Withdrawn Due to GI Adverse Events (AEs) | 114 of 2,238 | 167 of 2,246 | 4,484 | NCT00141102 | Trial comparisons |
| Celecoxib vs Oral Diclofenac Plus Omeprazole: serious adverse events | 61 of 2,223 | 61 of 2,237 | 4,460 | NCT00141102 | Trial comparisons |
| Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects With a Clinically Significant Decrease From Baseline in Hematocrit and/or Hemoglobin | 45 of 2,184 | 123 of 2,167 | 4,351 | NCT00141102 | Trial comparisons |
| Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects Hospitalized in Last 6 Months at the Post Trial Interview | 82 of 2,047 | 79 of 2,048 | 4,095 | NCT00141102 | Trial comparisons |
| Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects Alive at the Post Trial Interview | 2,018 of 2,047 | 2,023 of 2,048 | 4,095 | NCT00141102 | Trial comparisons |
| Quadruple Therapy (OBMT) 10 Days vs Triple Therapy (OAC) 7 Days: Number of Patients Experiencing Treatment Emergent Adverse Events. | 101 of 216 | 112 of 222 | 438 | NCT00669955 | Trial comparisons |
1 to 10 of 75
See all 75 comparisons in its trialsPapers from its trials150
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials2
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Paced Visual Serial Addition Test | 1 | 1 | ConductCognition |
| Symbol Coding | 1 | 1 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1503
GET https://conductscience.org/api/drugs/v1/CHEMBL1503/diseases?page=2